MedTrace Logo

Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

NCT01480219 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 467

Last updated 2013-03-11

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to assess the relationship (both crude and adjusted) between voriconazole utilization and the development of non-melanoma skin cancer among adult patients who received a lung or heart/lung transplant and were continuously enrolled in a large U.S. commercial health plan.

Conditions

  • Non-Melanoma Skin Carcinoma

Interventions

DRUG

voriconazole (Vfend)

Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.

OTHER

no voriconazole (Vfend)

Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.

Sponsors & Collaborators

  • University of Southern California

    collaborator OTHER

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-03-31
Completion
2012-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01480219 on ClinicalTrials.gov